Adherence to bisphosphonate treatment by elderly women

Menopause

Volumn 15, Issue 5, 2008, Pages 984-990

  Berecki Gisolf, Janneke ^a   Hockey, Richard ^a   Dobson, Annette ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Alendronate; Compliance; Osteoporosis; Persistence

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

ADULT; AGED; AGING; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DRUG WITHDRAWAL; FEMALE; HAZARD RATIO; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PHYSICAL ACTIVITY; POSTMENOPAUSE; PRESCRIPTION; PROPORTIONAL HAZARDS MODEL; SMOKING; SOCIAL STATUS; AUSTRALIA; DRUG SELF ADMINISTRATION; ECONOMICS; HEALTH BEHAVIOR; MIDDLE AGED; PATIENT ATTITUDE; POSTMENOPAUSE OSTEOPOROSIS; STATISTICS; WOMEN'S HEALTH;

AGED; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; HEALTH BEHAVIOR; HUMANS; LIFE STYLE; MEDICATION ADHERENCE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT ACCEPTANCE OF HEALTH CARE; PROPORTIONAL HAZARDS MODELS; QUEENSLAND; SELF ADMINISTRATION; WOMEN'S HEALTH;

EID: 58249092563     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e31816be98a     Document Type: Article

References (30)

1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. JAMA 2001;285:785-795.
2. The North American Menopause Society. Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society. Menopause 2006;13:340-367.
3. Rossini M, Bianchi G, Di Munno O, et al. Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 2006;17:914-921.
4. Papaioannou A, Kennedy CC, Dolovich L, Lau E, Adachi JD. Patient adherence to osteoporosis medications: problems, consequences and management strategies. Drugs Aging 2007;24:37-55.
5. Brookhart MA, Avorn J, Katz JN, et al. Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance. Am J Med 2007;120:251-256.
6. Solomon DH, Avorn J, Katz JN, et al. Compliance with osteoporosis medications. Arch Intern Med 2005;165:2414-2419.
7. Penning-van Beest FJ, Goettsch WG, Erkens JA, Herings RM. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clin Ther 2006;28:236-242.
8. Rabenda V, Mertens R, Fabri V, et al. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int 2007;18:1311-1317.
9. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004;15:1003-1008.
10. Kendler D, Kung AW, Fuleihan Gel H, et al. Patients with osteoporosis prefer once weekly to once daily dosing with alendronate. Maturitas 2004;48:243-251.
11. Cramer JA, Gold DT, Silverman SL, Lewiecki EM. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 2007;18:1023-1031.
12. Granger BB, Swedberg K, Ekman I, et al. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet 2005;366:2005-2011.
13. Tosteson AN, Grove MR, Hammond CS, et al. Early discontinuation of treatment for osteoporosis. Am J Med 2003;115:209-216.
14. Brown WJ, Bryson L, Byles JE, et al. Women's Health Australia: recruitment for a national longitudinal cohort study. Women Health 1998;28:23-40.
15. Lee C, Dobson AJ, Brown WJ, et al. Cohort profile: the Australian Longitudinal Study on Women's Health. Int J Epidemiol 2005;34:987-991.
16. Catalan VS, LeLorier J. Predictors of long-term persistence on statins in a subsidized clinical population. Value Health 2000;3:417-426.
17. McCallum J. The SF-36 in an Australian sample: validating a new, generic health status measure. Aust J Public Health 1995;19:160-166.
18. Ware JE, Kosinski M, Keller SD. SF-36 Physical and Mental Health Summary Scales: A User's Manual. Boston: The Health Institute, New England Medical Center, 1994.
19. Armstrong T, Bauman A, Davies J. Physical Activity Patterns of Australian Adults: Results of the 1999 National Physical Activity Survey. Canberra: Australian Institute of Health and Welfare, 2000.
20. Bauman A, Bellew B, Booth M, Hahn A, Stoker L, Thomas M. Towards Best Practice for the Promotion of Physical Activity in the Areas of NSW. Centre for Disease Prevention and Health, Sydney: New South Wales Health Department, 1996.
21. Reginster JY. Adherence and persistence: impact on outcomes and health care resources. Bone 2006;38(2 Suppl 2):S18-S21.
22. Bauer DC, Black D, Ensrud K, et al. Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. Arch Intern Med 2000;160:517-525.
23. Miller PD, Woodson G, Licata AA, et al. Rechallenge of patients who had discontinued alendronate therapy because of upper gastrointestinal symptoms. Clin Ther 2000;22:1433-1442.
24. White HD. Adherence and outcomes: it's more than taking the pills. Lancet 2005;366:1989-1991.
25. Adachi J, Lynch N, Middelhoven H, Hunjan M, Cowell W. The association between compliance and persistence with bisphosphonate therapy and fracture risk: a review. BMC Musculoskelet Disord 2007;8:97.
26. Yood RA, Emani S, Reed JI, Lewis BE, Charpentier M, Lydick E. Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 2003;14:965-968.
27. Wasnich RD, Bagger YZ, Hosking DJ, et al. Changes in bone density and turnover after alendronate or estrogen withdrawal. Menopause 2004;11:622-630.
28. Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006;296:2927-2938.
29. Bone HG, Hosking D, Devogelaer JP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004;350:1189-1199.
30. Rodan G, Reszka A, Golub E, Rizzoli R. Bone safety of long-term bisphosphonate treatment. Curr Med Res Opin 2004;20:1291-1300.